慢性乙型肝炎和肝硬化患者血清骨桥蛋白和TGF-β1水平变化*

doi:10.3969/j.issn.1672-5069.2017.02.032

Abstract

Zeng Bo， Li Yan.. Changes of serum osteopontin and TGF-β1 levels in patients with chronic hepatitis B and liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 240-241.

[1] 朱颖，沈圆圆，陈昕，等. 大鼠肝纤维化分期的流变特性分析.深圳大学学报（理工版），2013，30（2）:216-220.
[2] 张敏，杨丽莎，彭德珍，等. 慢性HBV感染不同免疫状态及乙肝肝硬化外周血T、B细胞亚群和NK细胞的变化及意义.实用医学杂志，2014，30（20）:3233-3236.
[3] Costa AN，Plymoth A，Santos-Silva D，et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer，2015，136（1）:172-181.
[4] 毛忠懿，吴雄健，陶立刚，等. ILK 和 TGF-β1在实验性大鼠肝纤维化中的表达和意义.安徽医药，2014，18（9）:1630-1633.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[6] 张姣丽，贾小芳，尹林，等. 免疫性肝纤维化大鼠血浆氨基酸浓度与肝纤维化程度的相关性研究. 中国生化药物杂志，2015，35（1）:52-56.
[7] Seifert LL，Heinzow H，Kabar I，et al. Successful anti-HCV therapy of a former intravenous drug user with sofosbuvir and daclatasvir in a peritranspant setting:a case report. Am J Case Rep，2016，24（17）:605-610.
[8] 殷宏娟，郜玉峰，叶珺，等. FIB-4指数对 ALT 小于2倍正常值上限的慢性 HBV 感染患者肝纤维化的诊断价值.安徽医科大学学报，2015，50（6）:812-815.
[9] 钱念东，黄萍，齐进，等. 血清骨桥蛋白与非酒精性脂肪性肝病患者肝纤维化的相关性分析. 检验医学，2014，29（11）:1154-1157.
[10] 黄大健，赵永忠，卢青，等. 转化生长因子-β1和骨桥蛋白在肝纤维化大鼠肝组织的表达及荔枝核总黄酮的干预.实用医学杂志，2013，29（22）:3646-3649.
[11] 黄大健，赵永忠. OPN与肝纤维化关系的研究进展.胃肠病学和肝病学杂志，2012，21（10）:916-918.
[12] 孔今波，任伟光，米红梅，等. 小鼠酒精性肝纤维化复合模型的建立及肝组织骨桥蛋白和转化生长因子β1的表达. 中华肝脏病杂志，2013，21（3）:207-212.
[13] 毛忠懿，吴雄健，陶立刚，等. ILK 和 TGF-β1在实验性大鼠肝纤维化中的表达和意义. 安徽医药，2014，18（9）:1630-1633.
[14] 陆伦根. 肝纤维化基础和临床研究热点问题. 实用肝脏病杂志，2016，19（1）:1-3.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Changes of serum osteopontin and TGF-β1 levels in patients with chronic hepatitis B and liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments